HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
- 15 January 2011
- Vol. 29 (11), 2011-2014
- https://doi.org/10.1016/j.vaccine.2011.01.001
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆Gynecologic Oncology, 2009
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 YearsThe Journal of Infectious Diseases, 2009
- Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa RicaVaccine, 2008
- Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated womenVaccine, 2008
- Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting InfectionJAMA, 2007
- Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 PseudovirionsHuman Vaccines, 2007
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesVirology, 2006
- Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.Proceedings of the National Academy of Sciences, 1995